J A Karlowsky

Summary

Affiliation: Focus Technologies
Country: USA

Publications

  1. pmc Factors influencing fluoroquinolone resistance
    Daniel F Sahm
    Emerg Infect Dis 9:1651-4. 2003
  2. pmc Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 46:1989-92. 2002
  3. ncbi request reprint Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA
    J A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 19:413-26. 2002
  4. pmc Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    J Clin Microbiol 41:3339-43. 2003
  5. pmc Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 46:2540-5. 2002
  6. pmc Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1681-8. 2003
  7. ncbi request reprint Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002)
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:963-70. 2003
  8. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Int J Antimicrob Agents 20:76-85. 2002
  9. ncbi request reprint Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting?
    James A Karlowsky
    Focus Technologies, 13665 Dulles Technology Drive, Herndon, VA 20171 4603, USA
    Curr Opin Pharmacol 2:487-92. 2002
  10. ncbi request reprint Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:183-7. 2003

Detail Information

Publications75

  1. pmc Factors influencing fluoroquinolone resistance
    Daniel F Sahm
    Emerg Infect Dis 9:1651-4. 2003
  2. pmc Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 46:1989-92. 2002
    ..Future studies will determine how linezolid clinical use in Canada affects its in vitro activity...
  3. ncbi request reprint Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA
    J A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 19:413-26. 2002
    ..In summary, ceftriaxone has retained its potent activity against the most commonly encountered Gram-positive and Gram-negative human pathogens despite widespread and ongoing clinical use for more than 15 years...
  4. pmc Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    J Clin Microbiol 41:3339-43. 2003
    ..1% of the results for E. aerogenes isolates and 6.0% of the results for E. cloacae isolates tested with the Vitek system...
  5. pmc Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 46:2540-5. 2002
    ..8 to 17.0%) from 1995 to 2001 but demonstrated considerable regional and institutional variation in 2001. Therapies other than SXT may need to be considered in some locations...
  6. pmc Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1681-8. 2003
    ..aeruginosa and A. baumannii were constant or decreased only marginally (</=3%) from 1998 to 2001. Greater decreases in susceptibility rates were, however, observed for fluoroquinolones and ceftazidime among P. aeruginosa isolates...
  7. ncbi request reprint Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002)
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:963-70. 2003
    ..53), and azithromycin (R2=0.41). Patient age, specimen source, and penicillin resistance were factors associated with antimicrobial resistance, particularly for nonfluoroquinolone antimicrobial agents...
  8. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Int J Antimicrob Agents 20:76-85. 2002
    ..However, a significant regional variation in S. pneumoniae susceptibilities was observed, as was a decrease in beta-lactamase rates among H. influenzae from the 1999-2000 to 2000-2001 respiratory seasons...
  9. ncbi request reprint Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting?
    James A Karlowsky
    Focus Technologies, 13665 Dulles Technology Drive, Herndon, VA 20171 4603, USA
    Curr Opin Pharmacol 2:487-92. 2002
    ....
  10. ncbi request reprint Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 36:183-7. 2003
    ..4% of ciprofloxacin-resistant isolates (683 of 6560) were resistant to nitrofurantoin. An association between resistance to fluoroquinolones and nitrofurantoin in E. coli has not been previously reported and warrants further study...
  11. pmc Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 1217 KP Hilversum, The Netherlands
    J Clin Microbiol 40:1063-6. 2002
    ..Pulsed-field gel electrophoresis of genomic DNA following SmaI digestion demonstrated identical patterns for each of the nine isolates, suggesting intra- and interhospital dissemination of a BLNAR clone...
  12. ncbi request reprint Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999
    J A Karlowsky
    MRL, Suite 200, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 18:121-7. 2001
    ..As resistance among uropathogens reaches clinically significant levels in many areas, continued regional surveillance is essential to ensure the provision of effective empiric therapy for urinary tract infections...
  13. pmc Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1790-7. 2003
    ..pneumoniae were susceptible to levofloxacin. If fluoroquinolones become a treatment option for pediatric patients, careful monitoring of fluoroquinolone susceptibilities will be increasingly important in future surveillance studies...
  14. ncbi request reprint Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network
    James A Karlowsky
    Focus Technologies Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 19:21-31. 2002
    ..TRUST centralized in vitro and electronic (TSN) surveillance methods provided an effective strategy for monitoring trends in resistance...
  15. ncbi request reprint In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren
    James A Karlowsky
    Focus Technologies, Inc formerly MRL, 13665 Dulles Technology Drive, Herndon, Virginia 20171, USA
    Diagn Microbiol Infect Dis 42:59-64. 2002
    ..The potent in vitro activity of cefditoren against a recent US collection of pneumococci as demonstrated in this study supports its continued development for oral empiric therapy in outpatients with respiratory tract infections...
  16. ncbi request reprint Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, Virginia 20171, USA
    Diagn Microbiol Infect Dis 42:53-8. 2002
    ..5 and 1 microg/mL inhibited 93.1 and 100% of M. catarrhalis isolates, respectively. We conclude that cefditoren is highly active in vitro against beta-lactamase-positive H. influenzae and M. catarrhalis...
  17. pmc Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis
    D F Sahm
    MRL, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 45:1037-42. 2001
    ..This longitudinal surveillance study of resistance in S. pneumoniae revealed that significant changes do occur in just a single year and supports the need for surveillance at least on an annual basis, if not continuously...
  18. pmc Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance
    D F Sahm
    MRL, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 45:267-74. 2001
    ....
  19. ncbi request reprint Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients
    M E Jones
    Focus Technologies, Herndon, VA 20171, USA
    Eur J Clin Microbiol Infect Dis 23:445-55. 2004
    ....
  20. ncbi request reprint Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001
    R Blosser-Middleton
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA
    Clin Microbiol Infect 9:431-6. 2003
    ..Despite variations in beta-lactamase production between different countries, > 99% of all isolates were susceptible to amoxicillin-clavulanate, ciprofloxacin, levofloxacin, and azithromycin...
  21. ncbi request reprint In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe
    I A Critchley
    Focus Technologies Inc, Herndon, VA 20171, USA
    Clin Microbiol Infect 8:214-21. 2002
    ..To assess the activities of levofloxacin and the comparator agents erythromycin, clarithromycin, azithromycin and doxycycline against atypical respiratory pathogens...
  22. ncbi request reprint Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000
    I A Critchley
    Focus Technologies, Inc, Herndon, Virginia, 20171 4603, USA
    Braz J Infect Dis 5:294-304. 2001
    ..Pneumoniae...
  23. ncbi request reprint In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001
    M E Jones
    Focus Technologies, Inc, Hilversum, The Netherlands
    Clin Microbiol Infect 9:590-9. 2003
    ..To assess the current (2001) activity of respiratory fluoroquinolones and comparator agents against respiratory pathogens isolated in European countries...
  24. ncbi request reprint Comparative activity of cefditoren and other oral beta-lactams against nonpneumococcal streptococci
    C Thornsberry
    Focus Technologies, Inc. (formerly MRL, Brentwood, TN, USA
    Chemotherapy 47:332-43. 2001
    ....
  25. ncbi request reprint Antimicrobial resistance among respiratory pathogens collected in Thailand during 1999-2000
    I A Critchley
    Focus Technologies, Inc, Herndon, Virginia 20171, USA
    J Chemother 14:147-54. 2002
    ..03 microg/ml) were the most active agents tested against M. catarrhalis. The results of this study may serve as a baseline for future studies to monitor antimicrobial susceptibilities among respiratory pathogens in Thailand...
  26. pmc Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000
    D F Sahm
    MRL, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 45:1402-6. 2001
    ..2% in the West South Central region. Given the current prevalence of multidrug resistance among urinary tract isolates of E. coli in the United States (7.1%), continued local, regional, and national surveillance is warranted...
  27. ncbi request reprint Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy
    Mark E Jones
    Focus Technologies Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA
    Int J Antimicrob Agents 23:240-6. 2004
    ....
  28. ncbi request reprint Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999
    Ian A Critchley
    Focus Technologies, Inc formerly MRL, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Diagn Microbiol Infect Dis 42:129-35. 2002
    ..Given the higher rates of macrolide resistance reported in other countries and the seriousness of invasive infections, continued antimicrobial surveillance of S. pyogenes in the United States would be prudent...
  29. ncbi request reprint Optimal use of antibiotic resistance surveillance systems
    I A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Clin Microbiol Infect 10:502-11. 2004
    ..It is clear that antibiotic resistance surveillance systems will continue to provide valuable data to health care providers, university researchers, pharmaceutical companies, and government and regulatory agencies...
  30. ncbi request reprint Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare
    M E Jones
    Focus Technologies, Herndon, VA, USA
    Clin Microbiol Infect 9:984-6. 2003
    ..anthracis isolates. Ceftriaxone demonstrated lower-level in vitro activity compared to penicillin-related compounds against B. anthracis. In vitro data from this study are in keeping with available guidelines...
  31. pmc In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy
    Richard P Wenzel
    Virginia Commonwealth University, Richmond Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:3089-98. 2003
    ..The present study demonstrated that established parenteral expanded-spectrum cephalosporin antimicrobial agents retain significant in vitro activity against many clinically important gram-negative pathogens...
  32. ncbi request reprint Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies
    James A Karlowsky
    Focus Bio Inova, Herndon, Virginia 20171 4603, USA
    Clin Infect Dis 40:S89-98. 2005
    ..Ongoing surveillance of P. aeruginosa is essential...
  33. pmc Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Ian A Critchley
    Focus Technologies, Inc formerly MRL, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 46:550-5. 2002
    ..influenzae strains, respectively; and 0.12 and 0.5 microg/ml for beta-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections...
  34. pmc In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations
    Daniel F Sahm
    Focus Technologies, Inc, Herndon, Virginia 20171, USA
    J Clin Microbiol 40:669-74. 2002
    ..3% were resistant. Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints for nonmeningeal isolates of S. pneumoniae decreased the number of isolates interpreted as intermediate by 10% and as resistant by 3 to 4%...
  35. pmc Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002
    Robert K Flamm
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 48:2431-6. 2004
    ..Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%)...
  36. ncbi request reprint In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698
    Denene Lofland
    Genesoft Pharmaceuticals, Inc, 7300 Shoreline Court, South San Francisco, CA, USA
    J Antimicrob Chemother 53:664-8. 2004
    ..BB-83698 is a peptide deformylase inhibitor currently in clinical trials in Europe. The purpose of this study was to provide additional susceptibility data from clinical isolates, including drug-resistant strains...
  37. ncbi request reprint The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002
    Mark E Jones
    Focus Technologies Inc, Dwarsdijk 30, 3612AP Tienhoven, The Netherlands
    Diagn Microbiol Infect Dis 47:579-86. 2003
    ..3%-0.7%) and in Asia (3.0-3.2%), but little or no change was seen in Mexico (3.8%-0%) or Brazil or South Africa, where no levofloxacin resistant isolates were detected in either study period...
  38. ncbi request reprint The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000
    Mark E Jones
    Focus Technologies Inc, Hilversum, The Netherlands
    Chemotherapy 48:232-7. 2002
    ..Increases in penicillin-resistant Streptococcus pneumoniae have been documented worldwide...
  39. ncbi request reprint Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative
    Mark E Jones
    Focus Technologies, Koninginneweg 11, 1217 KP, Hilversum, The Netherlands
    Int J Antimicrob Agents 19:119-23. 2002
    ..In summary, antimicrobial susceptibilities and the prevalence of beta-lactamase production in H. influenzae and M. catarrhalis in the United States has remained essentially unchanged from 1997-1998 to 1999...
  40. pmc In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV
    Mark E Jones
    Focus Technologies, Hilversum, The Netherlands Focus Technologies, Herndon, Virginia, USA
    Antimicrob Agents Chemother 46:1651-7. 2002
    ..aureus or S. pneumoniae was detected for the two NFQs. On the basis of their in vitro activities, these NFQ agents show potential for the treatment of infections caused by isolates resistant to currently available fluoroquinolones...
  41. ncbi request reprint In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli
    Ian A Critchley
    Focus Technologies, Herndon, VA 20171, USA
    Chemotherapy 49:44-8. 2003
    ..Combination antimicrobial therapy is often necessary to eradicate infections caused by gram-negative bacteria...
  42. pmc Longitudinal assessment of antipneumococcal susceptibility in the United States
    Mark E Jones
    Focus Technologies, Inc, Koniginneweg 11, 1217 KP Hilversum, The Netherlands
    Antimicrob Agents Chemother 46:2651-5. 2002
    ..4%; P < 0.001), and levofloxacin (0.3%; P = 0.017). Resistance to ceftriaxone (0.1%; P = 0.809) and moxifloxacin (0.03%; P = 0.570) decreased. Concurrently, multidrug resistance increased (P < 0.001) from 6.3% to 11.3%...
  43. pmc Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:1672-80. 2003
    ..Ongoing surveillance of Enterobacteriaceae will be particularly important to monitor changes in fluoroquinolone susceptibility, as well as changes in the prevalence of isolates resistant to multiple classes of antimicrobial agents...
  44. ncbi request reprint Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000
    Ian A Critchley
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 20:100-7. 2002
    ..Future studies to characterise resistant isolates by other molecular methods may ensure that the appropriate counter-measures can be taken to control the spread of resistant isolates...
  45. ncbi request reprint Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy
    Mark E Jones
    Focus Technologies, Dwarsdijk 30, 3612AP Tienhoven, Netherlands
    Int J Antimicrob Agents 22:406-19. 2003
    ..For P. aeruginosa piperacillin-tazobactam, amikacin, imipenem and ceftazidime were the most active compounds tested irrespective of region. Surveillance data should be considered when selecting empirical therapy for treating SSTI...
  46. pmc Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime
    James A Karlowsky
    Focus Technologies, Herndon, Virginia 20171, USA
    Antimicrob Agents Chemother 47:3155-60. 2003
    ..Whether such isolates have increased in prevalence over time remains unknown...
  47. pmc Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001
    Ian A Critchley
    Focus Technologies, Inc, Herndon, Virginia, USA
    Antimicrob Agents Chemother 47:1689-93. 2003
    ..This study may serve as a baseline to monitor future changes in the susceptibility of gram-positive species to daptomycin following its introduction into clinical use...
  48. ncbi request reprint The application of information technology to regional, national, and global surveillance of antimicrobial resistance
    Daniel F Sahm
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA
    Curr Pharm Des 9:969-74. 2003
    ..By virtue of information technology, large volumes of data can readily be managed and stored to allow timely and thorough analysis on institutional, regional, national, and global levels...
  49. ncbi request reprint Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001
    Ian A Critchley
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    J Antimicrob Chemother 51:639-49. 2003
    ..The results of this study provide a benchmark of the activity of daptomycin against contemporary European isolates and will serve as a baseline to monitor future changes in the susceptibility of these organisms to daptomycin...
  50. pmc Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2251-4. 2006
    ..0%) or nitrofurantoin (4.0%) was less common. Only 10.8% of isolates were resistant to ciprofloxacin alone. Fluoroquinolone-resistant isolates of E. coli from urine were frequently multidrug resistant...
  51. pmc In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis
    James A Karlowsky
    Antimicrob Agents Chemother 51:1580-1. 2007
  52. ncbi request reprint Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    Diagn Microbiol Infect Dis 58:283-7. 2007
    ..Antimicrobial-susceptible isolates demonstrated limited genetic relatedness, whereas 2 epidemiologic clusters containing a total of 40 isolates (57.1%) were identified among the multidrug-resistant isolates...
  53. ncbi request reprint Comparative review of the carbapenems
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 67:1027-52. 2007
    ..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections...
  54. ncbi request reprint Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination
    Alfred Gin
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Expert Rev Anti Infect Ther 5:365-83. 2007
    ..Piperacillin-tazobactam has an excellent safety and tolerability profile and continues to be a reliable option for the empiric treatment of moderate-to-severe infections in hospitalized patients...
  55. pmc Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005
    Kimberly A Nichol
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 52:1190-4. 2008
    ..Increased genetic homogeneity among the isolates from 2003 to 2005 (cluster analysis; P < 0.001) appeared to be due to expansion of existing clonal groups and to introduction of new PFGE types...
  56. pmc Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 52:1430-7. 2008
    ..aeruginosa, H. influenzae, Enterococcus spp., S. pneumoniae, and K. pneumoniae are the most common isolates recovered from clinical specimens in Canadian ICUs. A MDR phenotype is common for P. aeruginosa isolates in Canadian ICUs...
  57. doi request reprint In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study
    Andrew Walkty
    J Antimicrob Chemother 62:206-8. 2008
  58. doi request reprint Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 62:67-80. 2008
    ..aeruginosa), respectively...
  59. ncbi request reprint Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Department of Medicine, Health Sciences Centre, Winnipeg, Man, Canada
    Int J Antimicrob Agents 27:468-75. 2006
    ..This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates of E. coli and demonstrates the continuing evolution of resistance to antimicrobial agents...
  60. ncbi request reprint Tigecycline: a novel glycylcycline antibiotic
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada
    Expert Rev Anti Infect Ther 4:9-25. 2006
    ..e., nausea, vomiting and diarrhea) the most commonly reported. Tigecycline is a promising new broad-spectrum parenteral monotherapy for the treatment of patients with Gram-positive and -negative bacterial infections...
  61. ncbi request reprint Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents
    Mark E Jones
    J Antimicrob Chemother 51:196-9. 2003
  62. pmc In vitro antimicrobial activity of doripenem, a new carbapenem
    Yigong Ge
    Peninsula Pharmaceuticals, Alameda, California 94502, USA
    Antimicrob Agents Chemother 48:1384-96. 2004
    ..Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens...
  63. ncbi request reprint Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae
    James A Karlowsky
    J Antimicrob Chemother 51:467-8. 2003
  64. pmc Reinterpretation of susceptibility data using current NCCLS breakpoint criteria
    Mark E Jones
    Antimicrob Agents Chemother 47:830. 2003
  65. ncbi request reprint Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Clin Dermatol 9:245-54. 2008
    ..Further clinical studies are needed to determine the efficacy and safety of ceftobiprole and to define its role in patient care...
  66. pmc Relationship between antibiotic resistance in Streptococcus pneumoniae and that in Haemophilus influenzae: evidence for common selective pressure
    Mark E Jones
    Antimicrob Agents Chemother 46:3106-7. 2002
  67. pmc Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000
    Mark E Jones
    Antimicrob Agents Chemother 46:3104-5. 2002
  68. ncbi request reprint Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001
    James R Johnson
    Mucosal and Vaccine Research Center, Veterans Affairs Medical Center, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55417, USA
    J Infect Dis 190:1739-44. 2004
    ..Increases in antimicrobial resistance in Escherichia coli have been paralleled by an increasing incidence of E. coli sepsis, suggesting a possible link between resistance and virulence...
  69. ncbi request reprint Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Int J Antimicrob Agents 24:529-35. 2004
    ..In the meantime, appropriate antibiotic selection and optimal dosing strategies should aim to eradicate the causative pathogen before a resistant efflux mutant can emerge...
  70. ncbi request reprint Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000
    Clyde Thornsberry
    Focus Technologies Inc, Nashville, TN, USA answers com
    Clin Infect Dis 34:S4-S16. 2002
    ..6%) and M. catarrhalis (86.2%-96.8%) also varied by region. Notable variation in regional antimicrobial resistance rates (S. pneumoniae) and beta-lactamase production (H. influenzae, M. catarrhalis) exists throughout the United States...
  71. ncbi request reprint Faropenem: review of a new oral penem
    Kristen N Schurek
    Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada
    Expert Rev Anti Infect Ther 5:185-98. 2007
    ....
  72. ncbi request reprint Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae
    Yoav Keynan
    Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Scand J Infect Dis 39:828-30. 2007
    ..We describe a case of PLA caused by the hypermucoviscous, K1 capsular serotype of Klebsiella pneumoniae in a Canadian man and highlight the unique features of this increasingly common cause of liver abscess...
  73. doi request reprint Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections
    George G Zhanel
    MS 673 Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
    Expert Rev Anti Infect Ther 6:67-81. 2008
    ..Both telavancin and dalbavancin show promise as alternative treatments for patients with serious infections caused by resistant Gram-positive pathogens...
  74. pmc Not so pretty in pink: Staphylococcus cohnii masquerading as methicillin-resistant Staphylococcus aureus on chromogenic media
    Donald C Vinh
    J Clin Microbiol 44:4623-4. 2006
  75. pmc Thermostable DNase is superior to tube coagulase for direct detection of Staphylococcus aureus in positive blood cultures
    Philippe R S Lagacé-Wiens
    J Clin Microbiol 45:3478-9. 2007